Search Results - subject:"Fluorouracil"

Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal

Whyte, Sophie; Pandor, Abdullah; Stevenson, Matt - In: PharmacoEconomics 30 (2012) 12, pp. 1119-1132

the non-inferiority of oxaliplatin plus capecitabine (XELOX) compared with oxaliplatin plus 5-fluorouracil and folinic … oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine (i.e. FOLFOX or XELOX) was not recommended for the …

Persistent link: https://www.econbiz.de/10010614306

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer

Griffiths, Robert I.; Barron, Richard L.; Gleeson, … - In: PharmacoEconomics 30 (2012) 2, pp. 103-118

epirubicin); cyclophosphamide (C); taxane ([T]: paclitaxel or docetaxel); and fluorouracil (F). Patients were …

Persistent link: https://www.econbiz.de/10010614316

Cost Considerations in the Treatment of Colorectal Cancer

Jansman, Frank G.A.; Postma, Maarten J.; Brouwers, … - In: PharmacoEconomics 25 (2007) 7, pp. 537-562

colorectal cancer. The survival benefits of chemotherapy are only modest. For nearly 5 decades, 5-fluorouracil (5-FU) has been …

Persistent link: https://www.econbiz.de/10005243196

Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer

Limat, Samuel; Bracco-Nolin, Claire-Hélène; … - In: The European Journal of Health Economics 7 (2006) 2, pp. 107-113

Persistent link: https://www.econbiz.de/10005615775

Q-TWiST Analysis of Cyclophosphamide, Epirubicin, Fluorouracil versus Cyclophosphamide, Methotrexate, Fluorouracil Treatment for Premenopausal Women with Node-Positive Breast Cance...

Radice, Davide; Redaelli, Alberto - In: PharmacoEconomics 23 (2005) 1, pp. 69-75

axillary node-positive breast cancer receiving either cyclophosphamide, epirubicin and fluorouracil (CEF) or cyclophosphamide …, methotrexate, and fluorouracil (CMF), using data from a phase III clinical trial (National Cancer Institute of Canada Clinical …

Persistent link: https://www.econbiz.de/10005404873

A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada

Maroun, Jean A.; Asche, Carl; Romeyer, Francoise; … - In: PharmacoEconomics 21 (2003) 14, pp. 1039-1051

Background: Two randomised, controlled trials (n = 1396) comparing (i) intravenous fluorouracil (FU) plus oral folinic …

Persistent link: https://www.econbiz.de/10005404878

Cost Effectiveness of Adding Folinic Acid to Fluorouracil Plus Levamisole as Adjuvant Chemotherapy in Patients with Colon Cancer in Germany

Monz, Brigitta U.M.; Konig, Hans-Helmut; Leidl, Reiner; … - In: PharmacoEconomics 21 (2003) 10, pp. 709-719

Objective: To assess the cost effectiveness of the addition of folinic acid to fluorouracil plus levamisole in patients … fluorouracil plus levamisole (A, standard) or fluorouracil plus levamisole and folinic acid (B) for 12 months as adjuvant …: Adding folinic acid to the fluorouracil/levamisole regimen results in an increase in time to progression and survival in …

Persistent link: https://www.econbiz.de/10005590340

Can Sequential Administration Minimise the Cost of High Dose Chemotherapy?: An Economic Assessment in Inflammatory Breast Cancer

Marino, Patricia; Le Corroller, Anne-Gaelle; Palangie, Thao - In: PharmacoEconomics 21 (2003) 11, pp. 807-818

Objective: To evaluate the potential cost savings of using sequential high dose chemotherapy (HDC), with granulocyte colony-stimulating factor (filgrastim) and stem cell support, rather than single course administration of HDC with bone marrow transplantation (BMT) or peripheral blood stem cell...

Persistent link: https://www.econbiz.de/10005590492

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK

Aristides, Mike; Lees, Michael; Botwood, Nick; … - In: The European Journal of Health Economics 4 (2003) 3, pp. 216-221

Persistent link: https://www.econbiz.de/10009404272

Conjoint Analysis of a New Chemotherapy: Willingness to Pay and Preference for the Features of Raltitrexed versus Standard Therapy in Advanced Colorectal Cancer

Aristides, Mike; Chen, Jack; Schulz, Mark; Williamson, Eve - In: PharmacoEconomics 20 (2002) 11, pp. 775-784

therapy with fluorouracil plus leucovorin (FU-LV) from the perspective of patients with advanced colorectal cancer. The study …

Persistent link: https://www.econbiz.de/10005590404